Overcoming acquired resistance to TRAIL by chemotherapeutic agents and chain inhibitor I through distinct mechanisms

Hongbo Zhu, Lidong Zhang, Xuefeng Huang, John J. Davis, Dietmar A. Jacob, Fuminori Teranishi, Paul Chiao, Bingliang Fang

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

We recently found that repeated application of adenovectors expressing the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or recombinant TRAIL proteins to TRAIL-susceptible cancer cells resulted in selection and expansion of TRAIL-resistant cells. Overcoming this acquired resistance to TRAIL is desirable for TRAIL-mediated cancer therapy. Here we demonstrate that several chemotherapeutic agents, including 5-fluorouracil (5-FU) and mitomycin, and calpain inhibitor I, an NFκB inhibitor, can overcome acquired resistance to TRAIL in DLD1 colon cancer cells. The combination of TRAIL (approved gene symbol TNFSF10) gene therapy and 5-FU enhanced tumor suppression in vivo in nude mice bearing subcutaneous tumors established from TRAIL-resistant colon cancer cells. Whereas treatment with the combination of TRAIL and 5-FU or mitomycin led to enhanced activation of caspase-3, the combination of TRAIL and calpain inhibitor I resulted in enhanced activation of both caspase-8 and caspase-3. Moreover, mitomycin, but not 5-FU or calpain inhibitor I, induced overexpression of the BAX gene, which was correlated with enhanced TRAIL-induced cell killing in TRAIL-resistant DLD1 cells. Together, these results suggest that acquired resistance to TRAIL can be overcome by different mechanisms and that combinations of TRAIL gene therapy and chemotherapy may be a useful approach for cancer treatment.

Original languageEnglish
Pages (from-to)666-673
Number of pages8
JournalMolecular Therapy
Volume9
Issue number5
DOIs
Publication statusPublished - Jan 1 2004
Externally publishedYes

Fingerprint

Fluorouracil
Mitomycin
Neoplasms
Caspase 3
Genetic Therapy
Colonic Neoplasms
TNF-Related Apoptosis-Inducing Ligand
Caspase 8
Recombinant Proteins
Nude Mice
Genes
Therapeutics
Tumor Necrosis Factor-alpha
Apoptosis
Ligands
Drug Therapy
calpain inhibitors

Keywords

  • Combination therapy
  • Death receptor
  • Gene therapy
  • TRAIL

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Overcoming acquired resistance to TRAIL by chemotherapeutic agents and chain inhibitor I through distinct mechanisms. / Zhu, Hongbo; Zhang, Lidong; Huang, Xuefeng; Davis, John J.; Jacob, Dietmar A.; Teranishi, Fuminori; Chiao, Paul; Fang, Bingliang.

In: Molecular Therapy, Vol. 9, No. 5, 01.01.2004, p. 666-673.

Research output: Contribution to journalArticle

Zhu, Hongbo ; Zhang, Lidong ; Huang, Xuefeng ; Davis, John J. ; Jacob, Dietmar A. ; Teranishi, Fuminori ; Chiao, Paul ; Fang, Bingliang. / Overcoming acquired resistance to TRAIL by chemotherapeutic agents and chain inhibitor I through distinct mechanisms. In: Molecular Therapy. 2004 ; Vol. 9, No. 5. pp. 666-673.
@article{998599659b1b4731bbdbafe335be2651,
title = "Overcoming acquired resistance to TRAIL by chemotherapeutic agents and chain inhibitor I through distinct mechanisms",
abstract = "We recently found that repeated application of adenovectors expressing the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or recombinant TRAIL proteins to TRAIL-susceptible cancer cells resulted in selection and expansion of TRAIL-resistant cells. Overcoming this acquired resistance to TRAIL is desirable for TRAIL-mediated cancer therapy. Here we demonstrate that several chemotherapeutic agents, including 5-fluorouracil (5-FU) and mitomycin, and calpain inhibitor I, an NFκB inhibitor, can overcome acquired resistance to TRAIL in DLD1 colon cancer cells. The combination of TRAIL (approved gene symbol TNFSF10) gene therapy and 5-FU enhanced tumor suppression in vivo in nude mice bearing subcutaneous tumors established from TRAIL-resistant colon cancer cells. Whereas treatment with the combination of TRAIL and 5-FU or mitomycin led to enhanced activation of caspase-3, the combination of TRAIL and calpain inhibitor I resulted in enhanced activation of both caspase-8 and caspase-3. Moreover, mitomycin, but not 5-FU or calpain inhibitor I, induced overexpression of the BAX gene, which was correlated with enhanced TRAIL-induced cell killing in TRAIL-resistant DLD1 cells. Together, these results suggest that acquired resistance to TRAIL can be overcome by different mechanisms and that combinations of TRAIL gene therapy and chemotherapy may be a useful approach for cancer treatment.",
keywords = "Combination therapy, Death receptor, Gene therapy, TRAIL",
author = "Hongbo Zhu and Lidong Zhang and Xuefeng Huang and Davis, {John J.} and Jacob, {Dietmar A.} and Fuminori Teranishi and Paul Chiao and Bingliang Fang",
year = "2004",
month = "1",
day = "1",
doi = "10.1016/j.ymthe.2004.02.007",
language = "English",
volume = "9",
pages = "666--673",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Overcoming acquired resistance to TRAIL by chemotherapeutic agents and chain inhibitor I through distinct mechanisms

AU - Zhu, Hongbo

AU - Zhang, Lidong

AU - Huang, Xuefeng

AU - Davis, John J.

AU - Jacob, Dietmar A.

AU - Teranishi, Fuminori

AU - Chiao, Paul

AU - Fang, Bingliang

PY - 2004/1/1

Y1 - 2004/1/1

N2 - We recently found that repeated application of adenovectors expressing the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or recombinant TRAIL proteins to TRAIL-susceptible cancer cells resulted in selection and expansion of TRAIL-resistant cells. Overcoming this acquired resistance to TRAIL is desirable for TRAIL-mediated cancer therapy. Here we demonstrate that several chemotherapeutic agents, including 5-fluorouracil (5-FU) and mitomycin, and calpain inhibitor I, an NFκB inhibitor, can overcome acquired resistance to TRAIL in DLD1 colon cancer cells. The combination of TRAIL (approved gene symbol TNFSF10) gene therapy and 5-FU enhanced tumor suppression in vivo in nude mice bearing subcutaneous tumors established from TRAIL-resistant colon cancer cells. Whereas treatment with the combination of TRAIL and 5-FU or mitomycin led to enhanced activation of caspase-3, the combination of TRAIL and calpain inhibitor I resulted in enhanced activation of both caspase-8 and caspase-3. Moreover, mitomycin, but not 5-FU or calpain inhibitor I, induced overexpression of the BAX gene, which was correlated with enhanced TRAIL-induced cell killing in TRAIL-resistant DLD1 cells. Together, these results suggest that acquired resistance to TRAIL can be overcome by different mechanisms and that combinations of TRAIL gene therapy and chemotherapy may be a useful approach for cancer treatment.

AB - We recently found that repeated application of adenovectors expressing the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or recombinant TRAIL proteins to TRAIL-susceptible cancer cells resulted in selection and expansion of TRAIL-resistant cells. Overcoming this acquired resistance to TRAIL is desirable for TRAIL-mediated cancer therapy. Here we demonstrate that several chemotherapeutic agents, including 5-fluorouracil (5-FU) and mitomycin, and calpain inhibitor I, an NFκB inhibitor, can overcome acquired resistance to TRAIL in DLD1 colon cancer cells. The combination of TRAIL (approved gene symbol TNFSF10) gene therapy and 5-FU enhanced tumor suppression in vivo in nude mice bearing subcutaneous tumors established from TRAIL-resistant colon cancer cells. Whereas treatment with the combination of TRAIL and 5-FU or mitomycin led to enhanced activation of caspase-3, the combination of TRAIL and calpain inhibitor I resulted in enhanced activation of both caspase-8 and caspase-3. Moreover, mitomycin, but not 5-FU or calpain inhibitor I, induced overexpression of the BAX gene, which was correlated with enhanced TRAIL-induced cell killing in TRAIL-resistant DLD1 cells. Together, these results suggest that acquired resistance to TRAIL can be overcome by different mechanisms and that combinations of TRAIL gene therapy and chemotherapy may be a useful approach for cancer treatment.

KW - Combination therapy

KW - Death receptor

KW - Gene therapy

KW - TRAIL

UR - http://www.scopus.com/inward/record.url?scp=2442685407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442685407&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2004.02.007

DO - 10.1016/j.ymthe.2004.02.007

M3 - Article

C2 - 15120327

AN - SCOPUS:2442685407

VL - 9

SP - 666

EP - 673

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 5

ER -